Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Solid Biosciences Inc (SLDB) USD0.001

Sell:$9.18 Buy:$9.21 Change: $0.53 (5.44%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Change: $0.53 (5.44%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
Change: $0.53 (5.44%)
Market closed |  Prices as at close on 24 February 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies platform is engaged in the development of gene therapy candidates for DMD. Its lead program, SGT-001, is an adeno-associated virus (AAV) microdystrophin gene therapy candidate, which focuses on enabling the systemic delivery of a shortened yet functional version of the dystrophin gene. The Company is examining small molecule and biologic candidates that may help manage the secondary disorders associated with DMD. It is developing Wearable support for patients with DMD. The hardware of its assistive devices is composed of three technologies: force generating actuators (or motors), electrically controlled clutches, and harness technology called Flex Grip.

Contact details

141 Portland St Fl 5
United States
+1 (617) 3374680

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$588.78 million
Shares in issue:
60.45 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Ian Smith
    Chairman of the Board
  • Ilan Ganot
    President, Chief Executive Officer, Co-Founder, Director
  • Stephen DiPalma
    Interim Chief Financial Officer
  • Joel Schneider
    Chief Technology Officer and Head of Exploratory Research and Development
  • Carl Morris
    Chief Scientific Officer
  • Lynette Herscha
    Chief Legal Officer and Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.